LQDA - NASDAQ
Liquidia Corporation
$55.69
+1.5%Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
At a Glance
Live Snapshotlqda
Selling, General and Administrative Expenses
Last Annual Value
157.18M
3-Year CAGR
69%
5-Year CAGR
42%
10-Year CAGR
42%
Liquidia Corporation Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Liquidia Corporation NASDAQ:LQDA | 157.18M | 52.0% | 46.7% | 41.6% | |
 Cogent Biosciences, Inc. NASDAQ:COGT | 63.58M | 22.8% | 26.5% | 33.9% | |
 Structure Therapeutics Inc. NASDAQ:GPCR | 61.55M | 23.5% | 48.3% | N/A | |
 Denali Therapeutics Inc. NASDAQ:DNLI | 97.10M | -2.1% | 4.2% | 23.5% | |
 89bio, Inc. NASDAQ:ETNB | 39.62M | 11.0% | 15.3% | N/A | |
 ImmunityBio, Inc. NASDAQ:IBRX | 147.18M | 4.3% | 1.7% | 4.5% | |
 Arcus Biosciences, Inc. NYSE:RCUS | 110.00M | -2.0% | 8.8% | 39.5% | |
 Ocular Therapeutix, Inc. NASDAQ:OCUL | 118.30M | 16.7% | 12.0% | 20.9% | |
 Agios Pharmaceuticals, Inc. NASDAQ:AGIO | 180.28M | 14.6% | 8.2% | 13.5% |
Liquidia Corporation Fair Value Envelope
Related Guides
Continue your LQDA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.